Skip to main content
SpringerLink
Log in

Calcium Channel Blockers and Stroke Prevention

  • Chapter
  • First Online:
Metal Ion in Stroke

Part of the book series: Springer Series in Translational Stroke Research ((SSTSR))

  • 1104 Accesses

Abstract

Stroke is a major cause of morbidity, mortality, and disability. A large proportion of stroke burden is nowadays considered preventable, and in this sense, stroke prevention, either primary or secondary prevention, plays an important role. Among the modifiable risk factors for stroke, hypertension is the most important one, and this fact is mainly explained by its implication in virtually all the mechanisms by which stroke is produced. It is nowadays conclusively evidenced that lowering blood pressure reduces the risk of cardiovascular outcomes, including stroke, irrespective of age or individual risk factor profile. Among the different antihypertensive drugs, from the last systematic reviews, it is apparent that calcium channel blockers (CCBs) have a greater effect compared to other classes of drugs in reducing the risk of stroke. The chapter summarizes the role of CCBs in the field of stroke prevention analyzing: (1) results of the main randomized clinical trials on hypertensive patients testing the efficacy of a CCB vs. other classes of drugs, and reviewing the evidence brought by reviews and meta-analyses; (2) the possible pleiotropic actions and anti-atherosclerotic mechanisms related to CCBs; (3) the role of CCBs in the field of vascular dementia and vascular cognitive impairment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

ACE-inhibitors:

Angiotensin converting enzyme inhibitors

AD:

Alzheimer disease

ARBs:

Angiotensin receptor blockers

BP:

Blood pressure

CCBs:

Calcium channel blockers

CI:

Confidence interval

CT:

Computed tomography

HDL:

High-density lipoprotein

HR:

Hazard ratio

IMT:

Intima-media thickness

OR:

Odds ratio

RR:

Relative risk

VaD:

Vascular dementia

References

  • ALLHAT Officers Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288:2981–2997

    Article  Google Scholar 

  • Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury PL, Esmatjes E, Hricik D, Parikh CR, Raz I, Vanhille P, Wiegmann TB, Wolfe BM, Locatelli F, Goldhaber SZ, Lewis EJ, Irbesartan Diabetic Nephropathy Trial, Collaborative Study Group (2003) Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 138:542–549

    PubMed  CAS  Google Scholar 

  • Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB, Neaton JD, Grimm RH Jr, Hansson L, Lacourciere Y, Muller J, Sleight P, Weber MA, Williams G, Wittes J, Zanchetti A, Anders RJ, CONVINCE Research Group (2003) Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 289:2073–2082

    Google Scholar 

  • Borhani NO, Mercuri M, Borhani PA, Buckalew VM, Canossa-Terris M, Carr AA, Kappagoda T, Rocco MV, Schnaper HW, Sowers JR, Bond MG (1996) Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. JAMA 276:785–791

    Article  PubMed  CAS  Google Scholar 

  • Brovkovych VV, Kalinowski L, Muller-Peddinghaus R, Malinski T (2001) Synergistic antihypertensive effects of nifedipine on endothelium: concurrent release of NO and scavenging of superoxide. Hypertension 37:34–39

    Article  PubMed  CAS  Google Scholar 

  • Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM (2000) Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 356:366–372

    Article  PubMed  CAS  Google Scholar 

  • Byington RP, Miller ME, Herrington D, Riley W, Pitt B, Furberg CD, Hunninghake DB, Mancini GB (1997) Rationale, design, and baseline characteristics of the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT). Am J Cardiol 80:1087–1090

    Article  PubMed  CAS  Google Scholar 

  • Charo IF, Taub R (2011) Anti-inflammatory therapeutics for the treatment of atherosclerosis. Nat Rev Drug Discov 10(5):365–376

    Article  PubMed  CAS  Google Scholar 

  • Chen L, Haught WH, Yang B, Saldeen TGP, Parathasarathy S, Mehta JL (1997) Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of anti-atherosclerotic effects of vitamin E, lovastatin and amlodipine. J Am Coll Cardiol 30:569–575

    Article  PubMed  CAS  Google Scholar 

  • Chen N, Zhou M, Yang M, Guo J, Zhu C, Yang J, Wang Y, Yang X, He L (2010) Calcium channel blockers versus other classes of drugs for hypertension. Cochrane Database Syst Rev (8):CD003654

    Google Scholar 

  • Chui HC, Victoroff JL, Margolin D, Jagust W, Shankle R, Katzman R (1992) Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer’s Disease Diagnostic and Treatment Centers. Neurology 42:473–480

    Article  PubMed  CAS  Google Scholar 

  • Costanzo P, Perrone-Filardi P, Petretta M, Marciano C, Vassallo E, Gargiulo P, Paolillo S, Petretta A, Chiariello M (2009) Calcium channel blockers and cardiovascular outcomes: a meta-analysis of 175,634 patients. J Hypertens 27:1136–1151

    Article  PubMed  CAS  Google Scholar 

  • Czernichow S, Zanchetti A, Turnbull F, Barzi F, Ninomiya T, Kengne AP, Lambers Heerspink HJ, Perkovic V, Huxley R, Arima H, Patel A, Chalmers J, Woodward M, MacMahon S, Neal B, Blood Pressure Lowering Treatment Trialists’ Collaboration (2011) The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials. J Hypertens 29:4–16

    Google Scholar 

  • Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H (2002) LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359:995–1003

    Article  PubMed  CAS  Google Scholar 

  • Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J, ASCOT Investigators (2005) Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366:895–906

    Article  PubMed  Google Scholar 

  • de Jong GI, Traber J, Luiten PGM (1992) Formation of cerebrovascular anomalies in the ageing rats is delayed by chronic nimodipine application. Mech Ageing Dev 64:255–272

    Article  PubMed  Google Scholar 

  • Eickelberg O, Roth M, Block L-H (1997) Effects of amlodipine on gene expression and extracellular matrix formation in human vascular smooth muscle cells and fibroblasts: implications for vascular protection. Int J Cardiol 62(Suppl 2):S31–S37

    Article  PubMed  Google Scholar 

  • Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW (1998) The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 338:645–652

    Article  PubMed  CAS  Google Scholar 

  • Forette F, Seux ML, Staessen JA, Thijs L, Birkenhager WH, Babarskiene MR, Babeanu S, Bossini A, Gil-Extremera B, Girerd X, Laks T, Lilov E, Moisseyev V, Tuomilehto J, Vanhanen H, Webster J, Yodfat Y, Fagard R (1998) Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 352:1347–1351

    Article  PubMed  CAS  Google Scholar 

  • Forette F, Seux ML, Staessen JA, Thijs L, Babarskiene MR, Babeanu S, et al, Systolic Hypertension in Europe Investigators (2002) The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 62:2046–2052

    Google Scholar 

  • Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, Launer LJ, Laurent S, Lopez OL, Nyenhuis D, Petersen RC, Schneider JA, Tzourio C, Arnett DK, Bennett DA, Chui HC, Higashida RT, Lindquist R, Nilsson PM, Roman GC, Sellke FW, Seshadri S, on behalf of the American Heart Association Stroke Council, Council on Epidemiology and Prevention, Council on Cardiovascular Nursing, Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia (2011) Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association American Stroke Association. Stroke 42:2672–2713

    Google Scholar 

  • Grossman E, Messerli FH (2004) Calcium antagonists. Prog Cardiovasc Dis 47:34–57

    Article  PubMed  CAS  Google Scholar 

  • Hanon O, Forette F (2004) Prevention of dementia: lessons from SYST-EUR and PROGRESS. J Neurol Sci 226:71–74

    Article  PubMed  Google Scholar 

  • Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352:1685–1695

    Article  PubMed  CAS  Google Scholar 

  • Hansson L, Lindholm LH, Ekbom T, Dahlof B, Lanke J, Schersten B, Wester PO, Hedner T, de Faire U (1999) Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 354:1751–1756

    Article  PubMed  CAS  Google Scholar 

  • Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, Lanke J, de Faire U, Dahlof B, Karlberg BE (2000) Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 356:359–365

    Article  PubMed  CAS  Google Scholar 

  • Inzitari D, Poggesi A (2005) Calcium channel blockers and stroke. Aging Clin Exp Res 17(Suppl):16–30

    PubMed  Google Scholar 

  • Ishii N, Matsumura T, Kinoshita H, Fukuda K, Motoshima H, Senokuchi T, Nakao S, Tsutsumi A, Kim-Mitsuyama S, Kawada T, Takeya M, Miyamura N, Nishikawa N, Araki E (2010) Nifedipine induces peroxisome proliferator-activated receptor-γ activation in macrophages and suppresses the progression of atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 30:1598–1605

    Article  PubMed  CAS  Google Scholar 

  • Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ, ACCOMPLISH Trial Investigators (2008) Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 359:2417–2428

    Google Scholar 

  • Jansen I, Tfelt-Hansen P, Edvinsson L (1991) Comparison of the calcium entry blockers nimodipine and flunarizine on human cerebral and temporal arteries: role in cerebrovascular disorders. Eur J Clin Pharmacol 40(1):7–15

    Article  PubMed  CAS  Google Scholar 

  • Jorgensen B, Simonsen S, Endresen K, Forfang K, Vatne K, Hansen J, Webb J, Buller C, Goulet G, Erikssen J, Thaulow E (2000) Restenosis and clinical outcome in patients treated with amlodipine after angioplasty: results from the Coronary AngioPlasty Amlodipine REStenosis Study (CAPARES). J Am Coll Cardiol 35:592–599

    Article  PubMed  CAS  Google Scholar 

  • Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A, VALUE Trial Group (2004) Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363:2022–2031

    Google Scholar 

  • Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J 3rd (1961) Factors of risk in the development of coronary heart disease–six year follow-up experience. The Framingham Study. Ann Intern Med 55:33–50

    PubMed  CAS  Google Scholar 

  • Katz AM (1997) Molecular biology of calcium channels in the cardiovascular system. Am J Cardiol 80:17I–22I

    Article  PubMed  CAS  Google Scholar 

  • Kojima T, Miyauchi K, Yokoyama T, Yokoyama K, Kurata T, Suwa S, Kawamura M, Tamura H, Okazaki S, Inoue K, Fujiwara Y, Sumiyoshi M, Tanimoto K, Nakazato Y, Yamagami S, Hiro T, Komiyama N, Daida H (2011) Azelnidipine and amlodipine anti-coronary atherosclerosis trial in hypertensive patients undergoing coronary intervention by serial volumetric intravascular ultrasound analysis in Juntendo University (ALPS-J). Circ J 75:1071–1079

    Article  PubMed  CAS  Google Scholar 

  • Kramsch DM, Sharma RC (1995) Limits of lipid-lowering therapy: the benefits of amlodipine as an anti-atherosclerotic agent. J Hum Hypertens 9(Suppl 1):S3–S9

    PubMed  Google Scholar 

  • Langley MS, Sorkin EM (1989) Nimodipine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in cerebrovascular disease. Drugs 37:669–699

    Article  PubMed  CAS  Google Scholar 

  • Law MR, Morris JK, Wald NJ (2009) Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 338:b1665

    Article  PubMed  CAS  Google Scholar 

  • Lawes CM, Bennett DA, Feigin VL, Rodgers A (2004) Blood pressure and stroke: an overview of published reviews. Stroke 35:776–785, Corrected and republished in Stroke 35:1024

    Article  PubMed  Google Scholar 

  • Libby P (2000) Changing concepts of atherogenesis. J Intern Med 247:349–358

    Article  PubMed  CAS  Google Scholar 

  • Lichtlen PR, Hugenholtz PG, Rafflenbeul W, Hecker H, Jost S, Deckers JW (1990) Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Anti-atherosclerotiC Therapy (INTACT). Lancet 335:1109–1113

    Article  PubMed  CAS  Google Scholar 

  • Liu L, Wang JG, Gong L, Liu G, Staessen JA (1998) Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypertens 16:1823–1829

    Article  PubMed  CAS  Google Scholar 

  • Liu L, Zhang Y, Liu G, Li W, Zhang X, Zanchetti A, FEVER Study Group (2005) The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertension 23:2157–2172

    Article  CAS  Google Scholar 

  • Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, Go A, Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott MM, Meigs J, Mozaffarian D, Mussolino M, Nichol G, Roger VL, Rosamond W, Sacco R, Sorlie P, Roger VL, Thom T, Wasserthiel-Smoller S, Wong ND, Wylie-Rosett J, American Heart Association Statistics Committee and Stroke Statistics Subcommittee (2010) Heart disease and stroke statistics–2010 update: a report from the American Heart Association. Circulation 121:e46–e215

    Article  PubMed  Google Scholar 

  • Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ (2006) Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 367:1747–1757

    Article  PubMed  Google Scholar 

  • Lopez-Arrieta JM, Birks J (2000) Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst Rev (2):CD000147

    Google Scholar 

  • Lopez-Arrieta JM, Birks J (2001) Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst Rev (1):CD000147

    Google Scholar 

  • Malacco E, Mancia G, Rappelli A, Menotti A, Zuccaro MS, Coppini A, Shell Investigators (2003) Treatment of isolated systolic hypertension: the SHELL study results. Blood Press 12:160–167

    Google Scholar 

  • Mason RP (2002) Mechanisms of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine: review of the evidence. Atherosclerosis 165:191–199

    Article  PubMed  CAS  Google Scholar 

  • Mason RP, Walter MF, Trumbore MW, Olmstead EG Jr, Mason PE (1999) Membrane antioxidant effects of the charged dihydropyridine calcium antagonist amlodipine. J Mol Cell Cardiol 31:275–281

    Article  PubMed  CAS  Google Scholar 

  • Murray CJ, Lopez AD (1997) Global mortality, disability, and the contribution of risk factors: global Burden of Disease Study. Lancet 349:1436–1442

    Article  PubMed  CAS  Google Scholar 

  • National Institutes of Health: National Heart, Lung and Blood Institute (2009) NHLBI Morbidity and Mortality Chart Book. National Heart, Lung and Blood Institute [online]. http://www.nhlbi.nih.gov/resources/docs/2009_ChartBook.pdf

  • National Intervention Cooperative Study in Elderly Hypertensives Study Group (1999) Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. Hypertension 34:1129–1133

    Article  Google Scholar 

  • Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, Berman L, Shi H, Buebendorf E, Topol EJ, CAMELOT Investigators (2004) Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 292:2217–2225

    Article  PubMed  CAS  Google Scholar 

  • Norris K, Bourgoigne J, Gassman J, Hebert L, Middleton J, Phillips RA, Randall O, Rostand S, Sherer S, Toto RD, Wright JT Jr, Wang X, Greene T, Appel LJ, Lewis J, AASK Study Group (2006) Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial. Am J Kidney Dis 48(5):739–751

    Google Scholar 

  • Oates JA, Brown NJ (2001) Antihypertensive agents and the drug therapy of hypertension. In: Hardman JG, Limbird LE (eds) Goodman and Gilman’s The pharmacological basis of therapeutics, 10th edn, chapter 33. McGraw Hill, pp 871–900

    Google Scholar 

  • Ogihara T, Nakao K, Fukui T, Fukiyama K, Fujimoto A, Ueshima K, Oba K, Shimamoto K, Matsuoka H, Saruta T, CASE-J Trial Group (2008) The optimal target blood pressure for antihypertensive treatment in Japanese elderly patients with high-risk hypertension: a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial. Hypertens Res 31:1595–1601

    Article  PubMed  Google Scholar 

  • Opie LH, Schall R (2002) Evidence-based evaluation of calcium channel blockers for hypertension: equality of mortality and cardiovascular risk relative to conventional therapy. J Am Coll Cardiol 39:315–322

    Article  PubMed  CAS  Google Scholar 

  • Pahor M, Psaty BM, Alderman MH, Applegate WB, Williamson JD, Cavazzini C, Furberg CD (2000) Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. Lancet 356:1949–1954

    Article  PubMed  CAS  Google Scholar 

  • Pantoni L (2010) Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 9:689–701

    Article  PubMed  Google Scholar 

  • Pantoni L, Carosi M, Amigoni S, Mascalchi M, Inzitari D (1996) A preliminary open trial with nimodipine in patients with cognitive impairment and leukoaraiosis. Clin Neuropharmacol 19:497–506

    Article  PubMed  CAS  Google Scholar 

  • Pantoni L, Rossi R, Inzitari D, Bianchi C, Beneke M, Erkinjuntti T, Wallin A (2000) Efficacy and safety of nimodipine in subcortical vascular dementia: a subgroup analysis of the Scandinavian Multi-Infarct Dementia Trial. J Neurol Sci 175:124–134

    Article  PubMed  CAS  Google Scholar 

  • Pantoni L, del Ser T, Soglian AG, Amigoni S, Spadari G, Binelli D, Inzitari D (2005) Efficacy and safety of nimodipine in subcortical vascular dementia: a randomized placebo-controlled trial. Stroke 36:619–624

    Article  PubMed  CAS  Google Scholar 

  • Pantoni L, Poggesi A, Inzitari D (2009) Cognitive decline and dementia related to cerebrovascular diseases: some evidence and concepts. Cerebrovasc Dis 27(Suppl 1):191–196

    Article  PubMed  Google Scholar 

  • Pendlebury ST, Rothwell PM (2009) Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol 8:1006–1018

    Article  PubMed  Google Scholar 

  • Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, Mancia G, Cangiano JL, Garcia-Barreto D, Keltai M, Erdine S, Bristol HA, Kolb HR, Bakris GL, Cohen JD, Parmley WW, INVEST Investigators (2003) A calcium antagonist vs. a non-calcium ­antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 290:2805–2816

    Google Scholar 

  • Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GB, Miller ME, Riley W (2000) Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 102:1503–1510

    Article  PubMed  CAS  Google Scholar 

  • Poole-Wilson PA, Lubsen J, Kirwan BA, van Dalen FJ, Wagener G, Danchin N, Just H, Fox KA, Pocock SJ, Clayton TC, Motro M, Parker JD, Bourassa MG, Dart AM, Hildebrandt P, Hjalmarson A, Kragten JA, Molhoek GP, Otterstad JE, Seabra-Gomes R, Soler-Soler J, Weber S, A Coronary disease Trial Investigating Outcome with Nifedipine gastrointestinal therapeutic system investigators (2004) Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 364:849–857

    Article  PubMed  CAS  Google Scholar 

  • Poulter NR, Wedel H, Dahlof B, Sever PS, Beevers DG, Caulfield M, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J, Pocock S, ASCOT Investigators (2005) Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 366:907–913

    Google Scholar 

  • PROGRESS Collaborative Group (2001) Randomised trial of a perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358:1033–1041

    Article  Google Scholar 

  • Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS (2003) Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 289:2534–2544

    Article  PubMed  CAS  Google Scholar 

  • Román GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, Amaducci L, Orgogozo JM, Brun A, Hofman A, Moody DM, O’Brien MD, Yamaguchi T, Grafman J, Drayer BP, Bennett DA, Fisher M, Ogata J, Kokmen E, Bermejo E, Wolf PA, Gorelick PB, Bick KL, Pajeau AK, Bell MA, DeCarli C, Culebras A, Korczyn AD, Bogousslavky J, Hartmann A, Scheinberg P (1993) Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43:250–260

    Article  PubMed  Google Scholar 

  • Rosei EA, Dal Palù C, Leonetti G, Magnani B, Pessina A, Zanchetti A (1997) Clinical results of the verapamil in hypertension and atherosclerosis study. J Hypertens 15:1337–1344

    Article  PubMed  CAS  Google Scholar 

  • Rothwell PM (2010) Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension. Lancet 375:938–948

    Article  PubMed  Google Scholar 

  • Rothwell PM, Coull AJ, Giles MF, et al for the Oxford Vascular Study (2004) Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). Lancet 363:1925–1933

    Google Scholar 

  • Rothwell PM, Howard SC, Dolan E, O’Brien E, Dobson JE, Dahlöf B, Poulter NR, Sever PS, ASCOT-BPLA and MRC Trial Investigators (2010a) Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol 9:469–480

    Article  PubMed  CAS  Google Scholar 

  • Rothwell PM, Howard SC, Dolan E, O’Brien E, Dobson JE, Dahlöf B, Sever PS, Poulter NR (2010b) Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 375:895–905

    Article  PubMed  Google Scholar 

  • Sabbatini M, Tomassoni D, Amenta F (2001) Influence of treatment with Ca(2+) antagonists on cerebral vasculature of spontaneously hypertensive rats. Mech Ageing Dev 122:795–809

    Article  PubMed  CAS  Google Scholar 

  • Sandmann S, Unger T (1999) L- and T-type calcium channel blockade—the efficacy of the calcium channel antagonist mibefradil. J Clin Basic Cardiol 2:187–201

    CAS  Google Scholar 

  • Schrader J, Luders S, Kulschewski A, Hammersen F, Plate K, Berger J, Zidek W, Dominiak P, Diener HC, MOSES Study Group (2005) Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 36:1218–1226

    Article  PubMed  CAS  Google Scholar 

  • SHEP Cooperative Research Group (1991) Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 265:3255–3264

    Article  Google Scholar 

  • Simon A, Gariépy J, Moyse D, Levenson J (2001) Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes. Circulation 103:2949–2954

    Article  PubMed  CAS  Google Scholar 

  • Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR (1997) Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 277:813–817

    Article  PubMed  CAS  Google Scholar 

  • Spanish group of nicardipine study in vascular dementia (1999) An experimental, randomized, double-blind, placebo-controlled clinical trial to investigate the effect of nicardipine on cognitive function in patients with vascular dementia. Rev Neurol 28:835–845

    Google Scholar 

  • Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, Bulpitt CJ, de Leeuw PW, Dollery CT, Fletcher AE, Forette F, Leonetti G, Nachev C, O’Brien ET, Rosenfeld J, Rodicio JL, Tuomilehto J, Zanchetti A (1997) Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 350:757–764

    Article  PubMed  CAS  Google Scholar 

  • Staessen JA, Wang J-G, Thijs L (2003) Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens 21:1055–1076

    Article  PubMed  CAS  Google Scholar 

  • Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G, Strollo F (1998) Outcome results of the Fosinopril Versus Amlodipine cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 21:597–603

    Article  PubMed  CAS  Google Scholar 

  • Tulenko TN, Laury-Kleintop L, Walter MF, Mason RP (1997) Cholesterol, calcium and atherosclerosis: is there a role for calcium channel blockers in atheroprotection? Int J Cardiol 62(Suppl 2):55S–66S

    Article  Google Scholar 

  • Turnbull F, Blood Pressure Lowering Treatment Trialists’ Collaboration (2003) Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 362:1527–1535

    Article  PubMed  CAS  Google Scholar 

  • Turnbull F, Neal B, Ninomiya T, Algert C, Arima H, Barzi F, Bulpitt C, Chalmers J, Fagard R, Gleason A, Heritier S, Li N, Perkovic V, Woodward M, MacMahon S. Blood Pressure Lowering Treatment Trialists’ Collaboration (2008) Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 336:1121–1127

    Google Scholar 

  • Verdecchia P, Reboldi G, Angeli F, Gattobigio R, Bentivoglio M, Thijs L, Staessen JA, Porcellati C (2005) Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension 46:386–392

    Article  PubMed  CAS  Google Scholar 

  • Veterans Administration Cooperative Study Group on Antihypertensive Agents (1970) Effects of treatment on morbidity in hypertension II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA 213:1143–1152

    Article  Google Scholar 

  • Wang JG (2009) A combined role of calcium channel blockers and angiotensin receptor blockers in stroke prevention. Vasc Health Risk Manag 5:593–605

    Article  PubMed  CAS  Google Scholar 

  • Waters D, Lesperance J, Francetich M, Causey D, Theroux P, Chiang YK, Hudon G, Lemarbre L, Reitman M, Joyal M (1990) A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis. Circulation 82:1940–1953

    Article  PubMed  CAS  Google Scholar 

  • Webb AJ, Fischer U, Mehta Z, Rothwell PM (2010) Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. Lancet 375:906–915

    Article  PubMed  CAS  Google Scholar 

  • World Health Organization (1993) ICD-10 Classification of mental and behavioural disorders: diagnostic criteria for research. WHO, Geneva, pp 36–40

    Google Scholar 

  • Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G (2000) Effects of an angiotensin-converting-enzyme inhibitor ramipril in patients with coronary or other occlusive arterial disease. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. N Engl J Med 342:145–153

    Article  PubMed  CAS  Google Scholar 

  • Zanchetti A, Rosei EA, Dal Palu C, Leonetti G, Magnani B, Pessina A (1998) The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J Hypertens 16:1667–1676

    Article  PubMed  CAS  Google Scholar 

  • Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, Dal Palu C, Hansson L, Magnani B, Rahn KH, Reid JL, Rodicio J, Safar M, Eckes L, Rizzini P, European Lacidipine Study on atherosclerosis investigators (2002) Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 106:2422–2427

    Google Scholar 

  • Zhang X, Hintze TH (1998) Amlodipine releases nitric oxide from canine coronary microvessels: an unexpected mechanism of action of a cacium channel-blocking agent. Circulation 97:576–580

    Article  Google Scholar 

  • Zhu D, Li R, Liu G, Hua W (1999) Nimodipine inhibits calcium-independent nitric oxide synthase activity in transient focal cerebral ischemia rats and cultured mouse astroglial cells. Life Sci 65:221–231

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurological and Psychiatric Sciences, University of Florence, Largo Brambilla 3, Florence, 50134, Italy

    Anna Poggesi MD, PhD & Domenico Inzitari MD

Authors
  1. Anna Poggesi MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Domenico Inzitari MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Domenico Inzitari MD .

Editor information

Editors and Affiliations

  1. , Department of Biomedical Sciences, Ohio University, 346 Irvine Hall, Athens, 45701, Ohio, USA

    Yang V. Li

  2. Loma Linda University, 11234 Anderson Street, Room 2562B, Loma Linda, 92354, California, USA

    John H. Zhang

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media New York

About this chapter

Cite this chapter

Poggesi, A., Inzitari, D. (2012). Calcium Channel Blockers and Stroke Prevention. In: Li, Y., Zhang, J. (eds) Metal Ion in Stroke. Springer Series in Translational Stroke Research. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-9663-3_4

Download citation

Publish with us

Policies and ethics

Search

Navigation